Novo Nordisk A/s

Innate Pharma S.a.s.

Novo Nordisk-a/s Novo Alle

University of Genoa

Innate Pharma

Universita Di Genova

Kristian Kjaergaard

Stefan Zahn

Soeren Padkjaer

Peder Lisby Noerby

Soeren Lund

Henrik Sune Andersen

Alessandro Moretta

Pascale Andre

Peter Andreas Nicolai Reumert Wagtmann

Anders Svensson

Susanne Nedergaard Grell

Birgitte Friedrichsen

Jens Buchardt

Mette Dahl Andersen

Mariella Della Chiesa

Ivan Svendsen

Dorrit Baunsgaard

Albrecht Gruhler

Jesper Kastrup

Lars Hornum

Katarina Haakansson

Laurent Gauthier

Vibeke Westphal Stennicke

Francois Romagne

Anette Henriksen

Charlotte Wiberg

Anker Jon Hansen

Louise Hjerrild Zeuthen

Matthias Thorolfsson

Michael Wilken

Ole Hvilsted Olsen

Søren Berg Padkær

Soren Berg Padkjaer

Gert Bolt

Pieter Spee

Francois Romagné

Milchael Wilken

Matthias Thórólfsson

Petrus Johannes Loius Spee

Laurant Gauthier

Pieter Johannes Louis Spee

Soren Berg Padkaer

François Romagne

Søren Berg Padkaer

Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity

The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.

Anti-C5a receptor antibodies

The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.

The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.

Antagonistic DR3 ligands

The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.

The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated Factor VIII molecules fused to a polypeptide such as e.g. an antibody binding protein or a Fc domain.

Factor VIII fusion protein

Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Human anti-KIR antibodies

Nucleic acids encoding human anti-kir antibodies

Growing community of inventors

Ballerup, Denmark

Kristian Kjaergaard